

# Underuse of beta-blockers in patients with heart failure and COPD

**First published:** 26/10/2015

**Last updated:** 01/04/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS11387

### Study ID

27213

### DARWIN EU® study

No

### Study countries

☐ United Kingdom

### Study description

Cardiovascular comorbidity is common in chronic obstructive pulmonary disease (COPD). Retrospective cohort studies have shown putative benefits of beta-blockers in COPD. Although beta-blockers are established therapy in heart

failure (HF) guidelines, including for patients with COPD, there remain concerns regarding bronchoconstriction even with cardioselective beta-blockers. We aim to assess the real life use of beta-blockers for patients with HF who also have COPD.

---

## Study status

Finalised

## Research institutions and networks

### Institutions

#### Observational & Pragmatic Research Institute Pte (OPRI)

☐ United Kingdom

**First published:** 06/10/2015

**Last updated:** 19/08/2024

**Institution**

Educational Institution

Laboratory/Research/Testing facility

ENCePP partner

## Contact details

### Study institution contact

David Price dprice@opri.sg

Study contact

dprice@opri.sg

## Primary lead investigator

David Price

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Actual: 15/06/2015

---

### Study start date

Actual: 26/06/2015

---

### Date of final study report

Planned: 20/11/2015

Actual: 23/11/2016

## Sources of funding

- Other

## More details on funding

RiRL

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Drug utilisation

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

To assess the real life use of beta-blockers for patients with HF who also have COPD

## Study Design

## **Non-interventional study design**

Cross-sectional

## Study drug and medical condition

### **Anatomical Therapeutic Chemical (ATC) code**

(C07) BETA BLOCKING AGENTS

BETA BLOCKING AGENTS

(C09) AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

---

### **Medical condition to be studied**

Chronic obstructive pulmonary disease

Cardiac failure

## Population studied

### **Short description of the study population**

Patients with heart failure (HF) who also have chronic obstructive pulmonary disease (COPD).

---

### **Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Special population of interest

Other

---

## Special population of interest, other

Chronic obstructive pulmonary disease (COPD) and cardiac failure patients

---

## Estimated number of subjects

125000

# Study design details

## Data analysis plan

Treatments for HF will be compared between groups using multinomial logistic regression, and the odds ratios, 95% confidence intervals, and p-values will be reported.

## Data management

## Data sources

### Data source(s)

Optimum Patient Care Research Database

---

### Data sources (types)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

## CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

### Check logical consistency

Unknown

## Data characterisation

### Data characterisation conducted

Unknown